Rapport Therapeutics (RAPP) director granted 15,200 stock options at $35.21

Rhea-AI Filing Summary

Rapport Therapeutics, Inc. director John Maraganore received a grant of stock options covering 15,200 shares of common stock. The options have an exercise price of $35.21 per share and expire on June 10, 2036. Following this award, he holds 15,200 options directly.

The options vest upon the earlier of June 10, 2027 or the date of the next Annual Meeting of Stockholders, subject to his continued service on that vesting date. This is a compensation-related award rather than an open-market purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider MARAGANORE JOHN

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	15,200	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 15,200 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 15,200 options Exercise price: $35.21 per share Expiration date: June 10, 2036 +2 more

5 metrics

Options granted 15,200 options Stock Option (Right to Buy) grant to director

Exercise price $35.21 per share Exercise price for the stock option grant

Expiration date June 10, 2036 Option term end date

Underlying shares 15,200 shares Common stock underlying the options

Shares following transaction 15,200 options Total derivative holdings after grant

Key Terms

Stock Option (Right to Buy), exercise price, Annual Meeting of Stockholders, vest

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 35.2100"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Annual Meeting of Stockholders financial

"earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders"

vest financial

"The shares underlying this option shall vest upon the earlier of (i) June 10, 2027"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MARAGANORE JOHN

(Last) (First) (Middle)

RAPPORT THERAPEUTICS, INC.

99 HIGH STREET, SUITE 2100

(Street)

BOSTON MASSACHUSETTS 02110

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Rapport Therapeutics, Inc. [ RAPP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$35.21	06/10/2026		A		15,200		(1)	06/10/2036	Common Stock	15,200	$0	15,200	D

Explanation of Responses:

1. The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date.

	/s/ Troy Ignelzi, Attorney-in-Fact	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Rapport Therapeutics (RAPP) disclose in this Form 4?

Rapport Therapeutics disclosed that director John Maraganore received a stock option grant for 15,200 shares. The options are a compensation award, not an open-market trade, and give him the right to buy common shares at a fixed exercise price.

What are the key terms of John Maraganore’s stock options at Rapport Therapeutics (RAPP)?

The grant covers 15,200 shares of common stock at an exercise price of $35.21 per share. The options expire on June 10, 2036, providing a long-dated right to purchase shares at that fixed price if they vest.

When do the newly granted Rapport Therapeutics (RAPP) options vest for John Maraganore?

The options vest on the earlier of June 10, 2027, or the date of the next Annual Meeting of Stockholders. Vesting is conditioned on his continued service with the company through that vesting date.

Is the Rapport Therapeutics (RAPP) Form 4 transaction a stock purchase or sale?

No, the Form 4 shows a grant of stock options as compensation, not an open-market purchase or sale. The transaction gives a right to buy shares in the future at a set exercise price.

How many Rapport Therapeutics (RAPP) derivative securities does John Maraganore hold after this grant?

After the reported transaction, John Maraganore holds 15,200 stock options directly. Each option is exercisable for one share of common stock, subject to the vesting conditions described in the award terms.